FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

FDA rules Otsuka marketing claim overstates Rexulti efficacy

FDA rushes approval of dementia drug that quadruples risk of death

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA fast-tracking approval of new drugs — fewer trials, less info

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

FDA's accelerated drug approvals often lack confirmatory evidence

FDA Law Blog

Pharmaceutical payments to psychiatrists and betrayal of the

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

Takeda drug gets US FDA priority review status for esophagus